NEW YORK – Epizyme on Tuesday said it will initiate two basket studies in the second half of 2021 to evaluate the activity of tazemetostat (Tazverik) across various hematologic cancers and solid tumors.
NEW YORK – Epizyme on Tuesday said it will initiate two basket studies in the second half of 2021 to evaluate the activity of tazemetostat (Tazverik) across various hematologic cancers and solid tumors.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.